Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 1
2005 4
2006 3
2007 2
2008 1
2009 6
2010 1
2011 3
2012 3
2013 2
2014 8
2015 3
2016 3
2017 3
2019 4
2020 5
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Results by year
Filters applied: . Clear all
Page 1
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group. Gori S, et al. Among authors: buttitta f. Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25. Crit Rev Oncol Hematol. 2019. PMID: 31176273 Free article.
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. Lin L, et al. Among authors: buttitta f. Nat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9. Nat Genet. 2015. PMID: 25665005 Free PMC article.
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments.
Marchetti A, Di Lorito A, Felicioni L, Buttitta F. Marchetti A, et al. Among authors: buttitta f. Oncotarget. 2019 Dec 10;10(65):6957-6968. doi: 10.18632/oncotarget.27343. eCollection 2019 Dec 10. Oncotarget. 2019. PMID: 31857850 Free PMC article.
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, Viola P, Pullara C, Mucilli F, Buttitta F. Marchetti A, et al. Among authors: buttitta f. J Clin Oncol. 2011 Sep 10;29(26):3574-9. doi: 10.1200/JCO.2011.35.9638. Epub 2011 Aug 8. J Clin Oncol. 2011. PMID: 21825258
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment.
Buttitta F, Felicioni L, Lorito AD, Cortellini A, Irtelli L, Brocco D, Marino PD, Traisci D, D'Ostilio N, Paolo AD, Malorgio F, Assalone P, Felice SD, Fabbri F, Cianci G, Tursi M, Marchetti A. Buttitta F, et al. Oncotarget. 2020 Mar 17;11(11):982-991. doi: 10.18632/oncotarget.27517. eCollection 2020 Mar 17. Oncotarget. 2020. PMID: 32215186 Free PMC article.
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients.
Malapelle U, Rossi G, Pisapia P, Barberis M, Buttitta F, Castiglione F, Cecere FL, Grimaldi AM, Iaccarino A, Marchetti A, Massi D, Medicina D, Mele F, Minari R, Orlando E, Pagni F, Palmieri G, Righi L, Russo A, Tommasi S, Vermi W, Troncone G. Malapelle U, et al. Among authors: buttitta f. Crit Rev Oncol Hematol. 2020 Dec;156:103118. doi: 10.1016/j.critrevonc.2020.103118. Epub 2020 Oct 3. Crit Rev Oncol Hematol. 2020. PMID: 33038627 Review.
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.
Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C. Cortellini A, et al. Among authors: buttitta f. Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019. Onco Targets Ther. 2019. PMID: 30988620 Free PMC article.
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.
Pagni F, Malapelle U, Doglioni C, Fontanini G, Fraggetta F, Graziano P, Marchetti A, Guerini Rocco E, Pisapia P, Vigliar EV, Buttitta F, Jaconi M, Fusco N, Barberis M, Troncone G. Pagni F, et al. Among authors: buttitta f. Cancers (Basel). 2020 Jul 5;12(7):1800. doi: 10.3390/cancers12071800. Cancers (Basel). 2020. PMID: 32635634 Free PMC article.
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle.
Marchetti A, Di Lorito A, Buttitta F. Marchetti A, et al. Among authors: buttitta f. J Thorac Dis. 2017 Dec;9(12):4863-4866. doi: 10.21037/jtd.2017.11.105. J Thorac Dis. 2017. PMID: 29312678 Free PMC article. No abstract available.
Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network.
Fumagalli C, Guerini-Rocco E, Buttitta F, Iapicca P, You W, Mauri M, Felicioni L, Troncone G, Malapelle U, Scarpa A, Zamboni G, Calistri D, Barberis M, Marchetti A. Fumagalli C, et al. Among authors: buttitta f. J Clin Pathol. 2020 Oct 5:jclinpath-2020-206800. doi: 10.1136/jclinpath-2020-206800. Online ahead of print. J Clin Pathol. 2020. PMID: 33020174
55 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback